Advertisement
BMY vs GSK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. GlaxoSmithKline (GSK) Stock Comparison
Key Takeaways
- Both BMY and GSK have delivered similar year-to-date (YTD) gains of approximately 12%, outperforming broader market benchmarks.
- BMY provides a higher dividend yield at 4.29% compared to GSK's 3.26%, appealing to income-focused investors.
- GSK trades at a lower price-to-earnings (P/E) ratio of 14.52 versus BMY's 17.04, indicating potentially better value.
- BMY holds a slightly larger market capitalization of $120 billion against GSK's $109 billion.
- Recent market activity shows stability for both, with BMY benefiting from partnerships like Eliquis pricing initiatives and GSK from legal victories and pipeline progress.
- Tickeron's AI robots highlight diverse strategies that could complement holdings in pharmaceutical stocks like these.
Introduction
Bristol-Myers Squibb (BMY) and GlaxoSmithKline (GSK) represent two established players in the global pharmaceutical sector, both navigating patent cliffs, pipeline advancements, and macroeconomic pressures. This stock comparison analyzes their recent performance, valuation metrics, and market positioning, offering insights for dividend seekers, growth-oriented traders, and healthcare sector investors. In a market favoring defensive assets amid volatility, understanding relative strengths in business models, momentum, and sentiment helps inform portfolio decisions without speculative forecasts.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a leading biopharmaceutical company specializing in oncology, hematology, immunology, cardiovascular, and neuroscience therapies. Its portfolio includes blockbuster drugs like Eliquis and Opdivo. In recent market activity, BMY shares have traded around $59, with a 52-week range of $42.52 to $62.89 and YTD gains of 11.74% outperforming the S&P 500. Sentiment has been supported by partnerships, such as making Eliquis available via cost-plus pricing models, and anticipation around quarterly earnings. Low volatility combined with a robust dividend has bolstered stability, though legacy drug declines pose ongoing challenges offset by new launches.
GSK Overview and Recent Performance
GlaxoSmithKline (GSK), now GSK plc, focuses on pharmaceuticals, vaccines, and specialty medicines, with strengths in HIV treatments like Dovato and respiratory products like Arexvy. Shares have hovered near $54, within a 52-week range of $35.45 to $61.70, posting YTD returns of 11.91%. Recent weeks feature positive developments, including a partial court win in a dostarlimab licensing dispute and deals in lung imaging technology. These catalysts have sustained momentum despite short-term dips, underpinned by diverse revenue streams and consistent earnings beats in prior quarters.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ varied strategies like trend following, multi-agent signals, and volatility plays, with timeframes from 5 minutes to 60 days. Standout stats include annualized returns ranging from 50% to over 100%, win rates of 50-88%, and profit factors up to 4.53, often in sectors like semiconductors and leveraged ETFs. For instance, semiconductor-focused bots show 60-70% win rates with drawdowns under $12,000. This selection adapts to current conditions, offering real-time signals with risk controls. Traders can explore these to enhance strategies involving pharma stocks like BMY or GSK.
Head-to-Head Comparison
BMY emphasizes oncology and immunology for growth, contrasting GSK's vaccine and HIV franchises that provide steadier cash flows. Valuation-wise, GSK's lower P/E suggests undervaluation relative to BMY, while BMY counters with superior dividend yield. Recent momentum is balanced short-term, but GSK exhibits stronger multi-year gains (51% one-year vs. 29%). Risk factors include patent expirations for both, though BMY's low volatility profile edges it for conservatives. Sector exposure overlaps in healthcare, with sentiment lifted by BMY's pricing innovations and GSK's regulatory wins.
Tickeron AI Verdict
Tickeron's AI currently leans toward GSK with moderate conviction, driven by its lower valuation, robust multi-year trend consistency, and pipeline catalysts positioning it favorably amid healthcare rotations. BMY remains competitive via dividend stability, but relative momentum tips the scale probabilistically toward GSK.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and GSK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- GSK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 3 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 5 bearish.
- GSK’s TA Score: 3 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -5.10% price change this week, while GSK (@Pharmaceuticals: Major) price change was -4.14% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
GSK is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | GSK | BMY / GSK | |
| Capitalization | 110B | 103B | 107% |
| EBITDA | 15B | 10.1B | 149% |
| Gain YTD | 2.339 | 5.106 | 46% |
| P/E Ratio | 15.13 | 13.28 | 114% |
| Revenue | 48.5B | 32.8B | 148% |
| Total Cash | 10.5B | 3.44B | 305% |
| Total Debt | 46.4B | 19.1B | 243% |
BMY | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 41 | |
SMR RATING 1..100 | 25 | 27 | |
PRICE GROWTH RATING 1..100 | 58 | 51 | |
P/E GROWTH RATING 1..100 | 67 | 80 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (15) in the Pharmaceuticals Major industry is in the same range as BMY (18). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
GSK's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (100). This means that GSK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as GSK (27). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
GSK's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as BMY (58). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
BMY's P/E Growth Rating (67) in the Pharmaceuticals Major industry is in the same range as GSK (80). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
| BMY | GSK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 55% | N/A |
| Stochastic ODDS (%) | 3 days ago 61% | 3 days ago 46% |
| Momentum ODDS (%) | 3 days ago 58% | 3 days ago 43% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 56% |
| TrendWeek ODDS (%) | 3 days ago 56% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 58% |
| Advances ODDS (%) | 9 days ago 54% | 9 days ago 61% |
| Declines ODDS (%) | 3 days ago 54% | 3 days ago 54% |
| BollingerBands ODDS (%) | 3 days ago 58% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 39% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.